Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.

Molecular cancer therapeutics - 1 Jun 2013

Ihnen Maike, zu Eulenburg Christine, Kolarova Teodora, Qi Jing Wei, Manivong Kanthinh, Chalukya Meenal, Dering Judy, Anderson Lee, Ginther Charles, Meuter Alexandra, Winterhoff Boris, Jones Siân, Velculescu Victor E, Venkatesan Natarajan, Rong Hong-Mei, Dandekar Sugandha, Udar Nitin, Jänicke Fritz, Los Gerrit, Slamon Dennis J, Konecny Gottfried E

Abstract excerpt

Here, we investigate the potential role of the PARP inhibitor rucaparib (CO-338, formerly known as AG014699 and PF-01367338) for the treatment of sporadic ovarian cancer. We studied the growth inhibitory effects of rucaparib in a panel of 39 ovarian cancer cell lines that were each characterized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to DNA Fragmentation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Histones

Share to Indoles

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 23729402
DOI: 10.1158/1535-7163.MCT-12-0813
PMCID: PMC3963026

Genes

BRCA1
ATM
AURKA
BCCIP
BRCC3
EMSY
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23729402-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.PMID 23729402Read ↗

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Semantic proximity Read ↗

PARP Inhibitors for Cancer Therapy.Semantic proximity Read ↗

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsSemantic proximity Read ↗

PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancersSemantic proximity Read ↗

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.Semantic proximity Read ↗

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.Semantic proximity Read ↗

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.Semantic proximity Read ↗

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancerSemantic proximity Read ↗

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.Semantic proximity Read ↗

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.Semantic proximity Read ↗

The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directionsSemantic proximity Read ↗

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.